Neurocrine Biosciences, Inc.

NASDAQ:NBIX   3:59:51 PM EDT
104.85
-1.94 (-1.82%)
4:03:32 PM EDT: $104.43 -0.42 (-0.40%)
Positive Earnings Pre-Announcement

Neurocrine Biosciences Reports Q2 Results, Raises 2022 Ingrezza Sales Forecast

Published: 08/04/2022 21:04 GMT
Neurocrine Biosciences, Inc. (NBIX) - Neurocrine Biosciences Reports Second Quarter 2022 Financial Results and Raises 2022 Ingrezza Sales Guidance.
Neurocrine Biosciences Inc - Qtrly Loss per Share $0.18.
Neurocrine Biosciences Inc - Qtrly Adjusted Earnings per Share $0.84.
Neurocrine Biosciences Inc - Ingrezza (valbenazine) Q2 Net Product Sales of $350 Million.
Revenue is expected to be $374.43 Million
Adjusted EPS is expected to be $0.79

Next Quarter Revenue Guidance is expected to be $390.86 Million
Next Quarter EPS Guidance is expected to be $0.84

More details on our Analysts Page.